BOSTON--(BUSINESS WIRE)--Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that management will present at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 1:40pm ET at The Westin Grand Central in New York City.
A live webcast of the presentation can be accessed under the “Calendar of Events” page within the Investors & Media section of the company’s website at www.tokaipharma.com. A replay of the webcast will be archived on the Tokai website for 90 days following the date of the presentation.
About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of current second-generation anti-androgens, while also introducing a unique third mechanism – androgen receptor degradation. Tokai is developing galeterone for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s ARDA drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer. For more information on the company and galeterone, please visit www.tokaipharma.com.